>>Description of the research protocol "REACH RA"

Defining which remission criterion at Month 6 predicts remission at Month 12 in a real life clinical practice, in a cohort of rheumatoid arthritis patiens treated with etanercept (Enbrel)
Status : Ongoing (but closed to recruitment)

Additional details

Indication (or studied pathology) : Polyarthrite R
Brugmann identifier : REACH RA
EudraCT identifier : B707201421294
ClinicalTrials.gov identifier : NCT02202837


Involved department : Rheumatology
Principal investigator : Bentin
Sponsor : Pfizer
Contact : Clinical Research Unit

>This protocol was approved by the CHU Liège ethics committee.